# Scott Moonly

> Scott Moonly is a seed investor at Alta Life Sciences (Orange) backing Medical Device and Mobile. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alta Life Sciences](https://shizune.co/investors/profile/alta-life-sciences)
- Location: Orange, United States
- Total investments: 3
- Last investment: May 2021
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/scott-moonly-ph-d-96042a1

Scott Moonly is a seed investor at Alta Life Sciences in Orange focused on Medical Device and Mobile. Scott Moonly - General Partner @ Alta Life Sciences

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 2 | 67% |
| Mobile | 1 | 33% |
| Health Care | 1 | 33% |
| Neuroscience | 1 | 33% |
| Therapeutics | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series E | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M | Series E | May 27, 2021 |  |
| INBRAIN Neuroelectronics | INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $19.8M | Series A | Mar 26, 2021 |  |
| INBRAIN Neuroelectronics | INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $1.3M | Seed | Jun 11, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 2 deals together
- [ICF Capital](https://shizune.co/investors/profile/institut-catal-de-finances-icf) — VC Fund, 2 deals together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 1 deal together
- [BStartup - Banc Sabadell](https://shizune.co/investors/profile/bstartup-llc) — VC Fund, 1 deal together
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 1 deal together
- [Hildred Capital Partners](https://shizune.co/investors/profile/hildred-capital-partners) — VC Fund, 1 deal together

## About Alta Life Sciences

VC Fund · Barcelona, Spain

Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

5 contacts available at Alta Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Guy P. Nohra | Managing General Partner | https://shizune.co/investors/profile/guy-p-nohra |
| Scott Moonly | General Partner | https://shizune.co/investors/profile/scott-moonly |
| José Antonio Mesa | Partner | https://shizune.co/investors/profile/jos-antonio-mesa |
| Miguel Valls | General Partner | https://shizune.co/investors/profile/miguel-valls |
| Montserrat Vendrell | Partner | https://shizune.co/investors/profile/montserrat-vendrell |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Scott Moonly invest in?

Scott Moonly invests primarily in Medical Device, Mobile and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Scott Moonly last invest?

The most recent investment recorded for Scott Moonly closed in May 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co